I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
What I actually want to know is whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong.
If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
Answering the narrow version, because the broad one does not have a single answer. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
FDA_TrackerJim said:Orforglipron is the more interesting oral story because it is not a peptide at all.
No disagreement with FDA_TrackerJim. One condition attached. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.SurgeonPGH said:I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
Same position here, arrived at the long way round. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.
Clinical perspective, offered as context rather than as advice. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.